Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?

• Published in: Frontiers in neurology Vol. 12; p. 613834
• Main Authors: Savini, Giovanni, Asteggiano, Carlo, Paoletti, Matteo, Parravicini, Stefano, Pezzotti, Elena, Solazzo, Francesca, Muzic, Shaun I, Santini, Francesco, Deligianni, Xeni, Gardani, Alice, Germani, Giancarlo, Farina, Lisa M, Bergsland, Niels, Gandini Wheeler-Kingshott, Claudia A M, Berardinelli, Angela, Bastianello, Stefano, Pichiecchio, Anna
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.03.2021
• Subjects: motor neuron degeneration; muscle fat fraction; muscle MRI; Neurology; nusinersen (spinraza); spinal cord atrophy and degeneration; spinal muscular atrophy; muscle MRI; spinal cord atrophy and degeneration; motor neuron degeneration; quantitative magnetic resonance imaging; spinal muscular atrophy; nusinersen (spinraza); muscle fat fraction; treatment monitoring
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2021.613834

Nusinersen is a recent promising therapy approved for the treatment of spinal muscular atrophy (SMA), a rare disease characterized by the degeneration of alpha motor neurons (αMN) in the spinal cord (SC) leading to progressive muscle atrophy and dysfunction. Muscle and cervical SC quantitative magnetic resonance imaging (qMRI) has never been used to monitor drug treatment in SMA. The aim of this pilot study is to investigate whether qMRI can provide useful biomarkers for monitoring treatment efficacy in SMA. Three adult SMA 3a patients under treatment with nusinersen underwent longitudinal clinical and qMRI examinations every 4 months from baseline to 21-month follow-up. The qMRI protocol aimed to quantify thigh muscle fat fraction (FF) and water-T2 (w-T2) and to characterize SC volumes and microstructure. Eleven healthy controls underwent the same SC protocol (single time point). We evaluated clinical and imaging outcomes of SMA patients longitudinally and compared SC data between groups transversally. Patient motor function was stable, with only Patient 2 showing moderate improvements. Average muscle FF was already high at baseline (50%) and progressed over time (57%). w-T2 was also slightly higher than previously published data at baseline and slightly decreased over time. Cross-sectional area of the whole SC, gray matter (GM), and ventral horns (VHs) of Patients 1 and 3 were reduced compared to controls and remained stable over time, while GM and VHs areas of Patient 2 slightly increased. We found altered diffusion and magnetization transfer parameters in SC structures of SMA patients compared to controls, thus suggesting changes in tissue microstructure and myelin content. In this pilot study, we found a progression of FF in thigh muscles of SMA 3a patients during nusinersen therapy and a concurrent slight reduction of w-T2 over time. The SC qMRI analysis confirmed previous imaging and histopathological studies suggesting degeneration of αMN of the VHs, resulting in GM atrophy and demyelination. Our longitudinal data suggest that qMRI could represent a feasible technique for capturing microstructural changes induced by SMA and a candidate methodology for monitoring the effects of treatment, once replicated on a larger cohort.